louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01674998: Understanding the Natural History of REM Sleep Behavior Disorder
Official title: Understanding Autonomic Function in REM Sleep Behavior Disorder, Parkinsonism and Controls
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: REM Sleep Behavior Disorder
Keywords: REM Sleep Behavior Disorder
RBD
Dream
Dreams
Lead sponsor: The Parkinson's Institute
Sponsor class: OTHER
First posted: 2012-08-29
Enrollment: 15
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sleep disorders clinics Neurology practices Medical practices Sleep disorders support groups Web-based advertisements Community outreach

Brief summary: The purpose of this research study is to determine if safe, simple and non-invasive tests such as an electrocardiogram (EKG), a smell test, or a blood test could be used to identify neurological disorders before typical symptoms occur. Researchers believe that early identification of these disorders could lead to treatments to prevent, delay, or slow the development of one of more of these diseases. Some people with REM sleep behavior disorder (RBD) may go on to develop Parkinson's disease or another related neurological disorder, but many do not.


Eligibility criteria: Inclusion Criteria:

* Idiopathic REM sleep behavior

Exclusion Criteria:

* Parkinson's disease
* Alzheimer's disease
* Multiple system atrophy
* Dementia
* Minors

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sunnyvale
country: United States
facility: The Parkinson's Institute
state: California
Study officials:
References:
Clinical trial NCT03908398: Process-oriented and Outcome-oriented Visual Assessments
Official title: Comparison Process-oriented and Outcome-oriented Visual Assessments for the Evaluation of Hospital Cleanliness
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hospital Cleanliness
Keywords: ATP bioluminescence
Visual assessment
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2019-04-09
Enrollment: 504
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We compare the degrees of agreement between the ATP data, process-oriented visual assessment scores and outcome-oriented visual assessment scores after environmental cleaning.

Brief summary: This study aimed to compare the effectiveness of outcome-oriented visual assessment and process-oriented visual assessment using ATP bioluminescence test as a comparator in order to find out which method can be used to assess hospital cleanliness.

Detailed description: This study was conducted in a 17-bed adult medical intensive care unit at a medical center during December 2019 to December 2020. First of all, high-touch room surfaces were selected in patient rooms, including bed rails / controls, light switch, IV pump control, feeding pump control, monitor control, bedside table handle, call button, IV pole (grab area) and suction machine control. Then, Areas to be sampled on those high-touch room surfaces were identified. Whenever the housekeepers started to do terminal cleaning after patients were transferred or discharged, the researcher also started to observe directly the practices of cleaning at the same time and recorded "cleaned" if surfaces were cleaned and disinfected properly. Then, the researcher inspected surfaces and recorded "clean" if surfaces were free of dust, debris, and stains immediately after terminal cleaning.Ten minutes after terminal cleaning, Hygiena Ultrasnap Surface ATP test was performed to swab a standard area of 10 square centimeters on specific surfaces. After completing sampling, swabs were replace back in swab tube and all liquid in bulbs was expelled to activate the reaction. Once activated, samples were read right after shaking swab tube for 5-10 seconds.

Eligibility criteria: Inclusion Criteria:

* the environmental surfaces immediately after patients are discharged

Exclusion Criteria:

* no

Primary outcomes:
measure: ATP DATA
timeFrame: 10 minutes after environmental cleaning
measure: score of process-oriented visual assessments
timeFrame: immediately after environmental cleaning
measure: score of outcome-oriented visual assessments
timeFrame: immediately after environmental cleaning
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
Study officials:
affiliation: Taichung Veterans General Hospital Infection Control Center
name: Ying-Chun Chen, MS
role: STUDY_CHAIR
References:
Clinical trial NCT06536998: Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver）
Official title: Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver）
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Cancer
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2024-08-05
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated for liver cancer

Brief summary: This is the prospective, observational cohort study (Radiogenomics-Liver), which aims to explore the relationship between the imaging information of liver cancer patients, tumor microenvironment and the prognosis of liver cancer patients.


Eligibility criteria: Inclusion Criteria:

1. Patients treated for liver cancer in Wuhan Union Hospital from August 2024 to August 2027;
2. Aged \> 18 years old;
3. At least one CT scan or MRI scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria：

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than liver cancer;
4. Unclear pathological diagnosis.

Primary outcomes:
measure: Correlation analysis of sequencing results and body composition
timeFrame: 0.5 year
measure: Correlation analysis of sequencing results and tumor radiomic features
timeFrame: 0.5 year
Secondary outcomes:
measure: Constructing tumor microenvironment prediction model
timeFrame: 2 years
measure: Constructing a multi-dimensional prognostic prediction model
timeFrame: 3 years
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT02484898: SEEQ™ Performance Study
Official title: SEEQ™ Performance Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arrhythmia Type Unknown
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure
Sponsor class: INDUSTRY
First posted: 2015-06-30
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who require monitoring for the detection of non-lethal cardiac arrhythmias such as, but not limited to, supraventricular tachycardias (for example, atrial fibrillation, atrial flutter, paroxysmal SVTs), ventricular ectopy, bradyarrhythmias, and conduction disorders.

Brief summary: The purpose of the Medtronic SEEQ™ Performance study is to build further evidence on the clinical and economic benefit of the Medtronic market-released SEEQ™ Mobile Cardiac Telemetry System/External Cardiac Monitor System (MCT/ECM).


Eligibility criteria: Inclusion Criteria:

* Patient is indicated for a SEEQ™ MCT/ECM System for approved indications
* Patient is 18 years of age or older
* Patient is willing and able to provide consent and authorize the use and disclosure of health information
* Patient is willing and able to comply with the protocol

Exclusion Criteria:

* Patient has known allergy and/or hypersensitivity to adhesives or hydrogel.
* Patient has suspected potential life-threatening arrhythmias, or requires in-subject/in-hospital monitoring.
* Patient will undergo a medical procedure that would preclude full participate during the prescribed duration of the SEEQ™
* Patient has an implanted cardiac device, (e.g., pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy)

Primary outcomes:
measure: Diagnostic Yield of the SEEQ™ MCT/ECM System
timeFrame: 120 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Larkspur
country: United States
state: California
city: Simi Valley
country: United States
state: California
city: Aurora
country: United States
state: Colorado
city: Clearwater
country: United States
state: Florida
city: Palm Beach Gardens
country: United States
state: Florida
city: Sebring
country: United States
state: Florida
city: Rome
country: United States
state: Georgia
city: Jackson
country: United States
state: Mississippi
city: Henderson
country: United States
state: Nevada
Study officials:
affiliation: Medtronic
name: SEEQ Performance Study Clinical Team
role: STUDY_DIRECTOR
References:
Clinical trial NCT07003698: Postoperative Analgesic Efficacy of Recto Intercostal Nerve Block
Official title: Postoperative Analgesic Efficacy of Rectointercostal Nerve Block in Patients Undergoing Laparoscopic Cholecystectomy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Laparoskopic Cholecystectomy
Recto Intercostal Nerve Block
Keywords: Remifantanile conception
Acute pain
Postoperatif pain
Lead sponsor: Ankara Etlik City Hospital
Sponsor class: OTHER_GOV
First posted: 2025-06-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Laparoscopic cholecystectomy is a frequently performed surgery and the gold standard for the treatment of symptomatic gallstone disease. Although laparoscopic cholecystectomy is considered minimally invasive, it can cause moderate to severe pain in the postoperative period. Poorly controlled early postoperative pain impairs recovery quality and increases the risk of postoperative pulmonary complications, serving as a risk factor for chronic pain development.

Multimodal analgesia, including opioids, is used to manage pain following laparoscopic cholecystectomy. However, opioid treatment may lead to side effects such as postoperative nausea and vomiting (PONV), respiratory depression, and constipation.

The primary aim of this study is to evaluate the effect of recto-intercostal nerve block as part of multimodal analgesia on intraoperative opioid consumption and postoperative pain scores in patients undergoing laparoscopic cholecystectomy.


Eligibility criteria: Inclusion Criteria:

* 18 to 65 years old
* American Society of Anesthesiologists (ASA) physical status I-II-III
* Elective laparoscopic cholecystectomy surgery

Exclusion Criteria:

* Under 18 and over 65 years old
* ASA score IV and above
* Advanced co-morbidity
* History of bleeding diathesis
* Patient refusing the procedure
* Chronic opioid or analgesic use
* Patients who will operate under emergency conditions
* Block injection site infection
* Known allergy to local anesthetics
* Pregnancy

Primary outcomes:
measure: Intraoperative remifentanil consumption
timeFrame: During the intraoperative period
Secondary outcomes:
measure: Pain scores
timeFrame: First 24 hours after surgery
Other outcomes:
Locations:
city: Yenimahalle
country: Turkey
facility: Ankara Etlik City Hospital
state: Ankara
Study officials:
References:
Clinical trial NCT03457298: Lateral Ridge Augmentation Using a Volume Maintaining Collagen Scaffold Versus Allograft With Collagen Membrane.
Official title: Lateral Ridge Augmentation Using a Volume Maintaining Collagen Scaffold (Ossix Volumax) Versus Freeze-dried Bone Allograft (FDBA) With Collagen Membrane
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alveolar Ridge Augmentation, Dental Implants
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2018-03-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the current study is to compare lateral bone augmentation using the current gold standard (FDBA plus resorbable collagen membrane) versus Ossix Volumax as a stand-alone material.

Detailed description: One of the major problems in implant therapy is the need to regenerate bone after its resorption because of periodontal disease, traumatic extraction or surgical removal associated with treatment of invasive lesions.

Ossix Volumax is a novel volume maintaining collagen scaffold designed for bone augmentation in the atrophic ridge. It is 1-2 mm in thickness and undergoes mineralization progressing into ossification.

Thirty subjects requiring lateral bone augmentation of the maxilla or the mandible will be recruited study: Of these, twenty will be recruited and treated at the School of Dental Medicine, Harvard University, Boston, USA and ten (10) at the School of Graduate Dentistry, Rambam health care campus, Haifa, Israel.

Hypothesis:

The use of Ossix Volumax as a stand-alone augmentation material will results similar increase in the ridge width and volume compared to FDBA and barrier membrane when coupled together.

Eligibility criteria: Inclusion Criteria:

1. Patients age 18 to 85 years of age.
2. Alveolar ridge atrophy (\<5 mm) in the horizontal dimension requiring bone augmentation.
3. Implant therapy is scheduled for this site.
4. Willing to participate in the study and follow all the post-op visits.

Exclusion Criteria:

1. Systemic condition requiring prophylactic antibiotics.
2. The Introduction( I.V.) use of medication related osteonecrosis of the jaw ( MRONJ) or the use of such medication Per Os (P.O.) for five or more years, patients with at least three month drug holiday with a C-terminal cross-linking telopeptide (CTX) \> 150 pg/ml are eligible.
3. The use of medication known to impair healing (clinician desecration).
4. Unable to place implant for whatever reason.

Primary outcomes:
measure: Changes in socket width mm
timeFrame: baseline( prior to augmentation) and 9 months (implant placement)
Secondary outcomes:
measure: Changes in Ridge height mm
timeFrame: baseline( prior to augmentation) and 9 months (implant placement)
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus, Dept. of Periodontology
Study officials:
affiliation: Rambam Health Care Campus
name: Eli Machtei, DMD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00866398: Economic Evaluation German Drug-Eluting Stent Registry
Official title: Economic Evaluation German Drug-Eluting Stent Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Heart Disease
Keywords: coronary heart disease
chd
stent
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: IKKF GmbH
name: IHF Ludwigshafen
name: Cordis Medizinische Apparate GmbH
name: Boston Scientific Corporation
First posted: 2009-03-20
Enrollment: 3973
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with coronary heart disease, eligible for stent implantation.

Brief summary: Since the advent of coronary stents, in-stent restenosis has proven to be the major limitation of interventional cardiology, occurring in as many as 30% of patients. Drug-eluting stents are specifically designed to prevent the problem of in-stent restenosis. They consist of a selective anti-proliferative drug, sirolimus, a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, sirolimus elutes into the vessel wall and stops the process of neointimal hyperplasia, thereby significantly reducing the incidence of in-stent restenosis.

The study "Economic Evaluation of the German Drug-Eluting Stent Registry" examines the cost-effectiveness of drug-eluting stents compared to bare-metal stents (BMS) in patients with coronary stenosis. The goal of the study is to examine whether the guideline-supported implantation of SES, despite the higher initial cost, improves the quality and economic outcomes of the treatment of patients with coronary stenosis. Secondarily, the study evaluates patient quality of life, impairment of daily activities, and re-intervention rates.


Eligibility criteria: Inclusion Criteria:

* Indication for coronary stent implantation
* Additional inclusion criteria BMS cohort:

  * Acute Coronary Syndrome
  * Diabetes Mellitus
  * Previous Percutaneous Coronary Intervention/Coronary Artery Bypass Graft
  * 3-Vessel Disease

Primary outcomes:
measure: Cost equivalence of drug-eluting coronary stents versus bare metal stents
timeFrame: 12 months
Secondary outcomes:
measure: MACCE
timeFrame: 12 months
measure: Quality of life
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Charité University Medical Center
name: Stefan N Willich, Prof, MD, MPH
role: STUDY_DIRECTOR
References:
Clinical trial NCT02750098: Comparison of Aqueous and Plasma Glucose Level in Diabetic Patients
Official title: Comparison of Aqueous and Plasma Glucose Level in Diabetic Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diabetes Mellitus
Keywords: Diabetes Mellitus, Cataract, Aqueous humor
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2016-04-25
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Comparison of aqueous and plasma glucose level in diabetic patients

High glucose concentrations in aqueous humor are thought to be related of diabetic ocular injury, including cataract and diabetic keratopathy. The primary mechanisms are nonenzymatic glycation, oxidative stress and activation of polyol pathway. However, glucose concentrations in aqueous humor of diabetic patients was only examined in a few patients in the past.

This study will compare glucose concentration in blood plasma and aqueous humor in diabetic patients undergoing cataract surgery. Perioperative Hemoglobin A1c concentrations will also be examined. Correlation between these parameters will be analyzed.


Eligibility criteria: Inclusion Criteria:

- Diabetic patients planed for elective cataract surgery

Exclusion Criteria:

* s/p traumatic eye injury
* past or current uveitis
* patients using prescription eye drops except lubricants

Primary outcomes:
measure: Aqueous humor glucose concentration
timeFrame: Day of cataract surgery
Secondary outcomes:
measure: Plasma glucose concentrations
timeFrame: Day of cataract surgery
measure: Hemoglobin A1c
timeFrame: Perioperative month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02405598: Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
Official title: Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pompe Disease
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2015-04-01
Enrollment: 14
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: evaluate if beta 2-adrenergic agonist can have adjuvant effect to patients with infantile-onset Pompe disease under enzyme replacement therapy


Eligibility criteria: Inclusion Criteria:

1. Confirm diagnosis as Pompe disease
2. age 2 years or above
3. under at least 1 year regular recombinant human acid alpha glucosidase, and no dosage/frequency change in recent 3 months
4. Provide inform consent

Exclusion Criteria:

1. chronic heart disease such as arrhythmia, cardiomyopathy, cardiac infarction
2. history of seizure
3. history of diabetes mellitus
4. history of hyperthyroidism
5. hypokalemia
6. pregnant
7. allergy to β-agonists
8. under medications including diuretics, digoxin, beta-blockers, etc

Primary outcomes:
measure: 10% decrement of creatinine kinase
timeFrame: 6 months
measure: Improvement in 6-minutes walk test
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yin-Hsiu Chien, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05014698: IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
Official title: IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Differentiated Thyroid Cancer
Thyroid Cancer, Nonmedullary
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2021-08-20
Enrollment: 34
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).

Detailed description: The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC). Therefore, in the absence of a BAP1 and DICER1 abnormality, we offer to sequence your whole genome (WGS) or partial genome (genotyping) for a previously unknown genetic abnormality.

Furthermore, the discovery of new genes would be a major medical advance that could contribute to the identification of new therapeutic targets.

This research will be conducted at the University Hospital of Nantes and the Hospital of Vendée and 95 people should participate.

Eligibility criteria: Inclusion Criteria:

* Probant subjects
* Minor or adult subject
* Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
* Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
* Patient affiliated to a valid social security plan

Relative subjects

* Adult subjects
* Subject agreeing to sign the study consent and the biocollection consent
* Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes
* Patient affiliated to a social security plan

Exclusion Criteria:

* Subject refusing to participate
* Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
* Subjects under guardianship, curatorship or safeguard of justice or not socially insured
* Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)

Primary outcomes:
measure: Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer
timeFrame: within 2 years
Secondary outcomes:
measure: Number of phenotypes associated to genotypes of CDT
timeFrame: within 2 years
measure: Analysis of birthplace/family origin information
timeFrame: within 2 years
Other outcomes:
Locations:
city: La Roche-sur-Yon
country: France
facility: Vendée Hospital
city: Nantes
country: France
facility: Nantes University Hospital
Study officials:
References: